17-α hydroxyprogesterone caproate for the prevention of preterm birth

Women's Health

Volumn 8, Issue 1, 2012, Pages 21-30

  Gupta, Simi ^a   Roman, Ashley S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

17 hydroxyprogesterone caproate; preterm birth; prevention; progesterone

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CALCIUM CHANNEL BLOCKING AGENT; DEXAMETHASONE; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; MAGNESIUM SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROGESTERONE;

ARTICLE; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EVENING DOSAGE; FOOD AND DRUG ADMINISTRATION; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE SWELLING; LOADING DRUG DOSE; NONHUMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRURITUS; RISK REDUCTION; SUPPOSITORY; UNITED STATES; UTERINE CERVIX CERCLAGE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYPROGESTERONES; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; PRENATAL CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 83755161512     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.78     Document Type: Article

References (56)

1. Mathews TJ, Arialdi M, Osterman MJK, Strobino DM, Guyer B. Annual summary of vital statistics: 2008. Pediatrics 127, 146-157 (2011).
2. Lockwood CJ, Kuczynski E. Risk stratification and pathological mechanisms in preterm delivery. Pediatr. Perinat. Epidemiol. 15(Suppl. 2), 78-79 (2001).
3. Committee on Understanding Premature Birth and Assuring Healthy Outcomes, Board on Health Sciences Policy. Preterm Birth: Causes, Consequences and Prevention. Behrman RE, Butler AS (Eds). Institute of Medicine of the National Academies, The National Academies Press, Washington, DC, USA (2007).
4. Mercer BM, Goldenberg RL, Das A et al. The preterm prediction study: a clinical risk assessment system. Am. J. Obstet. Gynecol. 174, 1885-1893 (1996).
5. Meis P, Klebanoff M, Thom E et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N. Engl. J. Med. 346(24), 2379-2385 (2003). (Pubitemid 36682816)
6. American College of Obstetricians and Gynecologists Committee Opinion No. 475. Antenatal corticosteroid therapy for fetal maturation. Obstet. Gynecol. 117, 422-424 (2011).
7. American College of Obstetricians and Gynecologists Committee Opinion No. 455. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet. Gynecol. 115, 669-671 (2010).
8. Doyle LW, Crowther CA, Middleton P et al. Magnesium sulfate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev. 1, CD004661 (2009).
9. Gyetvai K, Hannah ME, Hodnett Ed, Ohlsson A. Tocolytic for preterm labor: a systematic review. Obstet. Gynecol. 94, 869-877 (1999). (Pubitemid 29490928)
10. Mercer BM, Miodovnik M, Thurnau GR et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. JAMA 278, 989-995 (1997). (Pubitemid 27430195)
11. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. Lancet 357, 979-988 (2001). (Pubitemid 32285389)
12. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labor: the ORACLE II randomized trial. Lancet 357, 989-994 (2001). (Pubitemid 32285390)
13. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am. J. Obstet. Gynecol. 188(2), 419-424 (2003). (Pubitemid 36249980)
14. O'Brien JM, Adair CD, Lewis DF et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 30, 687-696 (2007). (Pubitemid 47612689)
15. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med. 357(5), 462-469 (2007). (Pubitemid 47204875)
16. Hassan SS, Romero R, Vidyadhari D et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 38(1), 18-31 (2011).
17. Peltier M. Immunology of term and preterm labor. Reprod. Biol. Endocrinol. 1, 122-132 (2003).
18. Young A, Thomson AJ, Ledingham M, Jordan F, Greer IA, Norman JE. Immunolocalization of proinflammatory cytokines in myometrium, cervix, and fetal membranes during human parturition at term. Biol. Reprod. 66, 445-449 (2002). (Pubitemid 34101843)
19. Csapo AI, Pulkkinen M. Indispensibility of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet. Gynecol. Surv. 33, 69-81 (1978). (Pubitemid 8267883)
20. Peyron R, Aubeny E, Targosz V et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N. Engl. J. Med. 328, 1509-1513 (1993). (Pubitemid 23147779)
21. Xu H, Gonzalez M, Ofori E, Elovitz MA. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? Am. J. Obstet. Gynecol. 198, 314, e1-e8 (2008).
22. Kelly RW. Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response. Endocr. Rev. 15, 684-706 (1994).
23. Csapo A. Progesterone block. Am. J. Anat. 98, 273-291 (1956).
24. Zakar T, Hertelendy F. Progesterone withdrawal: key to parturition. Am. J. Obstet. Gynecol. 196, 289-296 (2007). (Pubitemid 46509609)
25. Patel S, Li A, Goodwin TM et al. Effect of 17 alpha hydroxyprogesterone caproate on the production of tumor necrosis factor-alpha and the expression of cyclooxygenase 2 in lipopolysaccharide-treated gravid human myometrial explants. J. Perinatol. 30, 584-589 (2010).
26. Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, Garfield RE. Progesterone but not 17 alpha hydroxyprogesterone caproate, inhibits human myometrial contractions. Am. J. Obstet. Gynecol. 199(4), 391.e1-391.e7 (2008).
27. Kuon RJ, Shi SQ, Maul H, Sohn C, Balducci J, Maner WL, Garfield RE. Pharmacological actions of progestins to inhibit cervical ripening and prevent delivery depend upon their properties, the route of administration and the vehicle. Am. J. Obstet. Gynecol. 202, 455.e1-455.e9 (2010).
28. Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A. 17 alpha hydroxyprogesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. Am. J. Perinatol. 25, 503-506 (2008).
29. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effect of 17 alpha hydroxyprogesterone caproate. Am. J. Obstet. Gynecol. 453, e1-e4 (2007).
30. Durnwald C, Lynch C, Walker H, Iams J. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time. Am. J. Obstet. Gynecol. 201, 410, e1-e5 (2009).
31. Onsrud M, Paus E, Haug E et al. Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Acta Obstet. Gynecol. Scand. 64, 519-523 (1985). (Pubitemid 15241030)
32. Caritis SN, Sharma S, Zhang S et al. Pharmacokinetics of 17-hydroxyprogesterone caproate (17OHCP) in singleton gestation. Reprod. Sci. 16(Suppl. 3), 85A (2009).
33. Caritis S, Sharma S, Venkataramana R et al. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am. J. Obstet. Gynecol. 205, 40, e1-e8 (2011).
34. Yan R, Fokina V, Hankins GD, Ahmed MS, Nanovskaya TN. The effect of esterases on 17 alpha-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol. 198(2), 229.e1-229.e5 (2008).
35. Yan R, Nanovskaya TN, Zharokova OL et al. Metabolism of 17 alpha-hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons. Biochem. Pharmacol. 75(9), 1848-1857 (2008).
36. Kimbel KH, Willenbrink J, Junkmann K. Distribution and excretion of 17 alpha-hydroxyprogesterone caproate in rats. Acta Endocrinol. 28(4), 502-506 (1958).
37. Hernauer SJ, Yan R, Patrikeeva SL et al. Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol. 199(2), 169.e1-169.e5 (2008).
38. Keirse M. Progestogen administration in pregnancy may prevent preterm delivery. Br. J. Obstet. Gynecol. 97, 149-154 (1990). (Pubitemid 20134285)
39. Johnson JWC, Austin KL, Jones GS et al. Efficacy of 17a- hydroxyprogesterone caproate in the prevention of preterm labor. N. Engl. J. Med. 293(14), 675-680 (1975).
40. Yemini M, Borenstein R, Dreazen E et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol. 151(5), 574-577 (1985). (Pubitemid 15049683)
41. Iams JD. Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC? Am. J. Obstet. Gynecol. 202, 409-410 (2010).
42. Rouse DJ, Caritis SN, Peaceman AM et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N. Engl. J. Med. 357(5), 454-461 (2007). (Pubitemid 47204874)
43. Caritis SN, Rouse DJ, Peaceman AM et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet. Gynecol. 113(2 Pt 1), 285-292 (2009).
44. Keeler SM, Kiefer D, Rochon M et al. A randomized trial of cerclage vs 17 alpha-hydroxyprogesterone caproate for treatment of short cervix. J. Perinat. Med. 37(5), 473-479 (2009).
45. Berghella V, Figueroa D, Szychowski JM et al. 17-alpha- hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am. J. Obstet. Gynecol. 202(4), 351.1-351.e6 (2010).
46. Durnwald CP, Momirova V, Rouse DJ et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-alpha-hydroxyprogesterone caproate. J. Matern. Fetal Neonatal Med. 23(12), 1360-1364 (2010).
47. Briery CM, Veillon EW, Klauser CK et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am. J. Obstet. Gynecol. 204, 54.e1-54.e5 (2011).
48. Rebarber A, Istwan NB, Russo-Stieglitz K et al. Increased incidence of gestational diabetes in women receiving prophylactic 17 alpha- hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30(9), 2277-2280 (2007). (Pubitemid 47359031)
49. Waters TP, Schultz BA, Mercer BM, Catalano PM. Effect of 17 alpha hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet. Gynecol. 114(1), 45-49 (2009).
50. Gyamfi C, Horton AL, Momirova V et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am. J. Obstet. Gynecol. 201(4), 392, e1-e5 (2009).
51. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 22, 251-270 (1980). (Pubitemid 11209782)
52. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet. Gynecol. 85, 141-149 (1995).
53. Northen AT, Norman GS, Anderson K et al. Follow up of children exposed to 17 alpha-hydroxy-progesterone caprote compared with placebo. Obstet. Gynecol. 110, 865-872 (2007). (Pubitemid 47508752)
54. Harper M, Zheng SL, Thom E et al. Cytokine gene polymorphisms and length of gestation. Obstet. Gynecol. 117(1), 125-130 (2011).
55. Manuck TA, Major HD, Varner MW et al. Progesterone receptor genotype, family history, and spontaneous preterm birth. Obstet. Gynecol. 115(4), 765-770 (2010).
56. Ehn NL, Cooper ME, Orr K et al. Evaluation of fetal and maternal genetic variation in the progesterone receptor gene for contributions to preterm birth. Pediatr. Res. 62(5), 630-635 (2007). (Pubitemid 351339003)